Since IL-36R receptor antagonist (IL-36Ra) is susceptible to inactivation and recombinant proteins have relatively short half-lives, we opted for an approach of IRAK4 or NF-κB inhibitor administered via TDDs and oral routes in DNFB-induced AD. The gene discussed is IRAK4; the disease is Alzheimer disease.